Research indicates that metformin can confer improved survival for patients with colorectal cancer that also have diabetes.
Older women with diabetes and cancer taking metformin saw an increase in survival.
Diabetes patients treated with the drug less likely to develop oropharyngeal and nasopharyngeal cancers.
Therapy with metformin use did not improve survival of patients with pancreatic ductal adenocarcinoma (PDAC), according to recent study data.
For patients with type 2 diabetes, metformin use is not associated with a significantly reduced risk of bladder cancer, according to a study.
The diabetes drug metformin is undergoing investigation as a potential treatment for different cancers in numerous clinical trials, but results vary.
Breast cancer cell growth, motility, and aggression is promoted by excess glucose, as experienced by patients with diabetes and metabolic syndrome, reports a new study.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|